Skip to content

An Observational Exploratory Study on Diagnosis and Surgical Treatment Strategies for Takayasu Arteritis

An Observational Exploratory Study on Diagnosis and Surgical Treatment Strategies for Takayasu Arteritis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097249
Enrollment
Unknown
Registered
2025-02-14
Start date
2024-04-12
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Takayasu Arteritis

Interventions

Endovascular intervention group for Takayasu arteritis:NA
Open surgery group for Takayasu arteritis:NA

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. Complies with the diagnostic criteria for Takayasu's arteritis established by the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) in 2022. 2. Ineffectiveness of medical treatment. 3. Indications for surgical intervention: (1) Imaging tests show severe stenosis (>70%) or occlusion of the aorta and its branches. (2) Refractory renovascular or aortic coarctation hypertension. (3) Manifestations of ischemia in organs such as the heart, brain, and limbs. (4) Aneurysmal changes in the aorta.

Exclusion criteria

Exclusion criteria: 1. Combined serious hematological and endocrine system lesions or combined tumors; 2. Combined serious heart, lung, liver, kidney and other important organs lesions, unable to tolerate anesthesia and surgery; 3. Subjects with acute or chronic infectious diseases (except tuberculosis); 4. Subjects with mental disorders or other reasons who are unable or unwilling to cooperate with the treatment; 5. Those who are pregnant before surgical intervention treatment.

Design outcomes

Primary

MeasureTime frame
Composite perioperative complications;Target vascular patency rate;

Secondary

MeasureTime frame
Quality of life scores;Disease activity;Immunosuppressive drug application;Antihypertensive drug application;Dehydration drug application;blood pressure level;Recurrence/exacerbation of symptoms;

Countries

China

Contacts

Public ContactLi Yongjun

Beijing Hospital

liyongjun4679@bjhmoh.cn+86 135 0109 9799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026